A multi-database pharmacovigilance study reveals distinctive immunosuppressive and opportunistic infection disproportionality signals with bevacizumab and temozolomide combination therapy in glioblastoma
BackgroundBevacizumab (BEV) plus temozolomide (TMZ) is increasingly used for glioblastoma, yet the immunosuppression-related adverse event spectrum and safety signals of this combination—including potential interaction effects and time-to-onset patterns—have not been comprehensively characterized in...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Frontiers Media S.A.
2026-03-01
|
| Σειρά: | Frontiers in Medicine |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1773599/full |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|